NEW YORK (360Dx) – For a time during the last decade, the drug testing business was something of a gold mine.
With the US opioid epidemic driving an increase in testing, physician practices, pain management clinics, and clinical laboratories billed Medicare and private insurers for billions of dollars per year in urine drug tests and related assays. A 2017 analysis by Kaiser Health News estimated that in 2014, spending on drug testing hit $8.5 billion.